NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Infinitopes Precision Immunomics

Infinitopes Precision Immunomics

Private
OxfordHealthcare & Life Scienceshttps://www.infinitopes.com/

Last Round

Seed

Jan 21, 2026

Total Funding Raised

$70.2M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Infinitopes Precision Immunomics is a clinical-stage biotechnology company that develops cancer vaccines using its precision antigen discovery platform and proprietary vector delivery systems.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

personalized cancer vaccinescancer immunotherapyneoantigen discoverycancer vaccineprecision medicineimmunopeptidomicstherapeutic cancer vaccinetumor antigenneoantigen predictionAI drug discoverybiotech R&Dcomputational biologyT-cell therapyoncology biotechcancer vaccine startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Infinitopes Precision Immunomics Comps

Public and private peers based on sector, stage, and business model.

Infinitopes Precision Immunomics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Infinitopes Precision Immunomics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJan 21, 2026
SeedApr 30, 2024

Key People

Founding team and executive leadership

Marcus Harrison

Interim Chief Operating Officer

Executive Team

Infinitopes Precision Immunomics Investors

Notable investors and investment history

Infinitopes Precision Immunomics investors
InvestorRounds
Innovate UKSeed
Cancer Research HorizonsSeed
Saras CapitalSeed
Meltwind AdvisorySeed
Kindred CapitalSeed
Amplify PartnersSeed
Manta Ray VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 21, 2026

    $35.1M raised in Seed funding.

  • Mar 20, 2025

    Jo Brewer appointed as Non-Executive Director

Infinitopes Precision Immunomics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Infinitopes Precision Immunomics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Infinitopes Precision Immunomics's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Employee Range29
Year Founded2021
Last FundingJan 21, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.